The research in Prasad lab focusses on the prediction of inter-individual differences in drug disposition and response. Prasad lab utilizes quantitative mass spectrometry (targeted and untargeted proteomics and metabolomics) to quantify drug metabolizing enzymes, transporters and endogenous metabolites in human tissues and biofluids. These data along with genomics information and in vitro data are integrated into physiologically-based pharmacokinetic (PBPK) models to predict variability in drug and endobiotic disposition. The integrated genomics-proteomics-metabolomics approach is further applied to discover specific biomarkers of drug metabolizing enzymes and transporters for predicting disposition and response of xeno- and endo-biotics in special populations such as pediatrics where clinical data are not generally available. For more information, please see ‘Drug dosing for children‘.
- Prediction of ontogeny mediated oral absorption and hepatic and renal disposition of drugs in children using physiologically-based pharmacokinetics (PBPK) modeling
- Discovery and validation of biomarkers for non-invasive and prospective prediction of drug disposition and response
- Role of drug metabolizing enzymes and transporters in steroid homeostasis
- ISSX North American New Investigator Award, International Society for the Study of Xenobiotics (ISSX), ISSX, 2018 Montreal, Canada.
- Editorial Board Member, Drug Metabolism and Disposition
- Translational and Clinical Pharmacology (TCP) Division’s Early Career Faculty Showcase ASPET, 2018, San Diego, CA
- Secretary/Treasurer, Drug Metabolism and Disposition Division, American Society for Pharmacology and Experimental Therapeutics (ASPET)